HIV とレトロ ウイルスのジャーナル オープンアクセス

抽象的な

Determine seroprevalence and associated risk factors of HBV infection among pregnant women and it relationship with blood transfusion at Hargeisa Group Hospital, Hargeisa, Somaliland

Abdullah Al-mamari

The measures are being put in place for the management of Hepatitis B virus (HBV) infection in Hargeisa, Somaliland among pregnant women remain the most vulnerable to develop chronic hepatitis. Routine screening in pregnant women is therefore necessary for effective control. However, the performance of the commonly used the HBsAg sero test strips have been available. Also, identifying the risk factors of transmission in pregnant women is importance for the implementation of preventive measures. Hence, the goal of this study was to determining sero-prevalence and associated risk factors with HBV infection among pregnant women.

Material & Methods: The study area was carried out at Hargeisa group hospital in Somaliland from May 2018 up to December 2018. The researcher was collected research pregnancy woman data through questionnaire & used diagnostics methods such asHepatitis B surface antigen (HBsAg) test, antibodies test (HBsAb) by used anti-card test and ELIZA system.

Results and Discussion: The results in the current study shown that the pregnancy with hepatitis BV and  it relation with appeared some symptoms  in our study was 24(46.15%) of patients appeared they have cirrhosis symptom, 12(23.08%) of patients  answered they have liver failure, while 9(17.31%) of patients appeared yellowish of eyes & skin and 5(9.62%) showed hepatic cancer.

Conclusion: The results of current study showed that the sero-prevalence of HBV infections in pregnant women and it relationship with blood transfusion & other factors is high in Hargeisa Group Hospital, Hargeisa, Somaliland. However, further studies are needed to assess the role of other demographic and clinical risk factors. Urgent action is required to improve hepatitis B infection control measures to reduce dependence on blood transfusions and make new policies for treatment of anemia in HGH.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません